Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methylphenidate | 28 | 2021 | 97 | 7.680 |
Why?
|
| Central Nervous System Stimulants | 17 | 2019 | 221 | 3.730 |
Why?
|
| Dexmethylphenidate Hydrochloride | 6 | 2018 | 12 | 2.330 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 7 | 2018 | 189 | 2.240 |
Why?
|
| Ethanol | 12 | 2017 | 893 | 2.180 |
Why?
|
| Delayed-Action Preparations | 6 | 2018 | 120 | 0.880 |
Why?
|
| Motor Activity | 8 | 2013 | 621 | 0.840 |
Why?
|
| Stereoisomerism | 12 | 2017 | 169 | 0.820 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 4 | 2013 | 82 | 0.790 |
Why?
|
| Chromatography, Gas | 1 | 2019 | 31 | 0.670 |
Why?
|
| Amphetamines | 1 | 2017 | 10 | 0.600 |
Why?
|
| Precision Medicine | 1 | 2018 | 111 | 0.590 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 5 | 2011 | 59 | 0.500 |
Why?
|
| Biological Availability | 6 | 2019 | 79 | 0.500 |
Why?
|
| Esterification | 5 | 2014 | 25 | 0.490 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 4 | 2013 | 21 | 0.480 |
Why?
|
| Dopamine | 3 | 2014 | 474 | 0.480 |
Why?
|
| Dopamine Agonists | 1 | 2014 | 68 | 0.470 |
Why?
|
| Drug Interactions | 6 | 2017 | 289 | 0.470 |
Why?
|
| Affect | 1 | 2015 | 218 | 0.460 |
Why?
|
| Behavior, Animal | 3 | 2012 | 470 | 0.420 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2017 | 1745 | 0.380 |
Why?
|
| Locomotion | 1 | 2011 | 135 | 0.370 |
Why?
|
| Cross-Over Studies | 5 | 2017 | 260 | 0.360 |
Why?
|
| Animals | 19 | 2014 | 20881 | 0.310 |
Why?
|
| Carboxylesterase | 2 | 2021 | 4 | 0.310 |
Why?
|
| Area Under Curve | 4 | 2016 | 238 | 0.310 |
Why?
|
| Child Behavior Disorders | 1 | 2008 | 69 | 0.300 |
Why?
|
| Mice, Inbred C57BL | 6 | 2012 | 2791 | 0.290 |
Why?
|
| Humans | 27 | 2021 | 68618 | 0.280 |
Why?
|
| Male | 19 | 2017 | 37321 | 0.280 |
Why?
|
| Administration, Cutaneous | 3 | 2011 | 56 | 0.270 |
Why?
|
| Patient Care Team | 1 | 2008 | 311 | 0.260 |
Why?
|
| Mice | 10 | 2012 | 8474 | 0.260 |
Why?
|
| Central Nervous System Depressants | 1 | 2007 | 182 | 0.250 |
Why?
|
| Food-Drug Interactions | 1 | 2005 | 4 | 0.250 |
Why?
|
| Cognition Disorders | 1 | 2008 | 342 | 0.250 |
Why?
|
| Dopamine Agents | 1 | 2005 | 56 | 0.240 |
Why?
|
| Administration, Oral | 5 | 2017 | 411 | 0.240 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 805 | 0.220 |
Why?
|
| Brain | 3 | 2011 | 2176 | 0.210 |
Why?
|
| Drug Synergism | 2 | 2015 | 260 | 0.210 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2003 | 152 | 0.200 |
Why?
|
| Adult | 10 | 2017 | 21403 | 0.200 |
Why?
|
| Steroid Hydroxylases | 3 | 2004 | 19 | 0.180 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2004 | 62 | 0.180 |
Why?
|
| Skin Absorption | 2 | 2011 | 7 | 0.180 |
Why?
|
| Biotransformation | 2 | 2011 | 69 | 0.160 |
Why?
|
| Child | 4 | 2021 | 6405 | 0.160 |
Why?
|
| Dosage Forms | 1 | 2018 | 20 | 0.160 |
Why?
|
| Half-Life | 2 | 2017 | 96 | 0.160 |
Why?
|
| Vitamin D | 4 | 2007 | 516 | 0.150 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 567 | 0.150 |
Why?
|
| Female | 14 | 2017 | 38074 | 0.140 |
Why?
|
| Young Adult | 4 | 2017 | 5717 | 0.140 |
Why?
|
| Biomarkers | 4 | 2021 | 1593 | 0.140 |
Why?
|
| Microsomes, Liver | 3 | 2004 | 44 | 0.140 |
Why?
|
| Structure-Activity Relationship | 2 | 2008 | 420 | 0.130 |
Why?
|
| Carboxylic Ester Hydrolases | 2 | 2021 | 26 | 0.130 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 4 | 2007 | 8 | 0.120 |
Why?
|
| Age Factors | 2 | 2017 | 1864 | 0.120 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2013 | 51 | 0.110 |
Why?
|
| Hydrolysis | 1 | 2013 | 144 | 0.110 |
Why?
|
| Flavonolignans | 1 | 2013 | 2 | 0.110 |
Why?
|
| Silymarin | 1 | 2013 | 7 | 0.110 |
Why?
|
| Isomerism | 2 | 2011 | 63 | 0.110 |
Why?
|
| Dinoprost | 3 | 2013 | 27 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 848 | 0.110 |
Why?
|
| Sex Factors | 3 | 2005 | 1266 | 0.100 |
Why?
|
| Transdermal Patch | 1 | 2011 | 21 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 304 | 0.090 |
Why?
|
| Intestinal Absorption | 1 | 2011 | 41 | 0.090 |
Why?
|
| Adolescent | 2 | 2017 | 8912 | 0.090 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 120 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 139 | 0.090 |
Why?
|
| Pharmacogenetics | 2 | 2008 | 47 | 0.090 |
Why?
|
| Body Temperature | 2 | 2007 | 116 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2012 | 705 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2007 | 381 | 0.080 |
Why?
|
| Rats | 3 | 2013 | 5300 | 0.080 |
Why?
|
| Dermatitis, Contact | 1 | 2009 | 14 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 2083 | 0.080 |
Why?
|
| Racemases and Epimerases | 1 | 2008 | 2 | 0.080 |
Why?
|
| Amphetamine | 1 | 2009 | 77 | 0.080 |
Why?
|
| Liver | 2 | 2021 | 1118 | 0.080 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2007 | 52 | 0.070 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2007 | 112 | 0.070 |
Why?
|
| Phospholipases A | 1 | 2007 | 41 | 0.070 |
Why?
|
| Respiratory Mechanics | 1 | 2007 | 33 | 0.070 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2007 | 41 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 181 | 0.070 |
Why?
|
| Norepinephrine | 1 | 2007 | 276 | 0.070 |
Why?
|
| Dextroamphetamine | 1 | 2006 | 30 | 0.070 |
Why?
|
| Cholesterol | 1 | 2007 | 331 | 0.070 |
Why?
|
| Camellia sinensis | 1 | 2005 | 9 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 951 | 0.070 |
Why?
|
| Tea | 1 | 2005 | 23 | 0.070 |
Why?
|
| Protein Binding | 2 | 2006 | 1027 | 0.060 |
Why?
|
| Methamphetamine | 1 | 2007 | 132 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 94 | 0.060 |
Why?
|
| Healthy Volunteers | 2 | 2017 | 78 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2006 | 120 | 0.060 |
Why?
|
| Symporters | 1 | 2005 | 27 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 659 | 0.060 |
Why?
|
| Radioligand Assay | 1 | 2005 | 109 | 0.060 |
Why?
|
| Steroid 16-alpha-Hydroxylase | 1 | 2004 | 1 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2005 | 201 | 0.060 |
Why?
|
| Receptors, Serotonin | 1 | 2005 | 74 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2004 | 11 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2005 | 35 | 0.060 |
Why?
|
| Receptors, Dopamine | 1 | 2005 | 119 | 0.060 |
Why?
|
| Cell Line | 2 | 2008 | 1752 | 0.060 |
Why?
|
| Sex Characteristics | 1 | 2007 | 295 | 0.060 |
Why?
|
| Heart Rate | 1 | 2007 | 568 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 81 | 0.060 |
Why?
|
| Phenotype | 1 | 2007 | 947 | 0.060 |
Why?
|
| Lupus Nephritis | 1 | 2005 | 193 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 290 | 0.050 |
Why?
|
| Time Factors | 2 | 2009 | 4655 | 0.050 |
Why?
|
| Calcium | 1 | 2007 | 929 | 0.050 |
Why?
|
| Mutation | 1 | 2008 | 1213 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 370 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2021 | 94 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2005 | 718 | 0.050 |
Why?
|
| Child, Preschool | 1 | 2008 | 3187 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2007 | 1451 | 0.050 |
Why?
|
| Kinetics | 3 | 2008 | 1047 | 0.040 |
Why?
|
| Cocaine | 1 | 2005 | 555 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2003 | 931 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 742 | 0.040 |
Why?
|
| Hydroxylation | 2 | 2007 | 41 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2007 | 204 | 0.030 |
Why?
|
| Substrate Specificity | 2 | 2008 | 234 | 0.030 |
Why?
|
| Vitamin D3 24-Hydroxylase | 2 | 2004 | 24 | 0.030 |
Why?
|
| Capsules | 2 | 2005 | 18 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2004 | 22 | 0.030 |
Why?
|
| Transfection | 2 | 2007 | 782 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 2077 | 0.030 |
Why?
|
| Milk Thistle | 1 | 2013 | 7 | 0.030 |
Why?
|
| F2-Isoprostanes | 1 | 2013 | 14 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2007 | 1692 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2003 | 7029 | 0.020 |
Why?
|
| Drug Stability | 1 | 2011 | 71 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2008 | 8 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2008 | 15 | 0.020 |
Why?
|
| Point Mutation | 1 | 2008 | 97 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 137 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 207 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2008 | 99 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 302 | 0.020 |
Why?
|
| Xanthomatosis, Cerebrotendinous | 1 | 2007 | 1 | 0.020 |
Why?
|
| COS Cells | 1 | 2007 | 155 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2007 | 71 | 0.020 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2007 | 14 | 0.020 |
Why?
|
| Pyrones | 1 | 2007 | 4 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 159 | 0.020 |
Why?
|
| Kidney Cortex | 1 | 2007 | 19 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 386 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2007 | 86 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2006 | 1 | 0.020 |
Why?
|
| Serotonin | 1 | 2007 | 144 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 1 | 2006 | 11 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 2006 | 31 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2007 | 47 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 2006 | 124 | 0.020 |
Why?
|
| Receptors, Muscarinic | 1 | 2006 | 44 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1753 | 0.020 |
Why?
|
| Ion Channels | 1 | 2006 | 72 | 0.020 |
Why?
|
| Cues | 1 | 2011 | 654 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 1015 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2007 | 396 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 137 | 0.020 |
Why?
|
| Microglia | 1 | 2007 | 143 | 0.020 |
Why?
|
| Rabbits | 1 | 2007 | 509 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2007 | 397 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2006 | 89 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 149 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 2005 | 14 | 0.020 |
Why?
|
| Mice, Inbred NZB | 1 | 2005 | 37 | 0.020 |
Why?
|
| Nitrites | 1 | 2005 | 53 | 0.020 |
Why?
|
| Nitrates | 1 | 2005 | 61 | 0.020 |
Why?
|
| Catechin | 1 | 2005 | 26 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2006 | 173 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2006 | 99 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 2007 | 279 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1083 | 0.020 |
Why?
|
| Lysine | 1 | 2005 | 96 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 627 | 0.020 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2004 | 3 | 0.020 |
Why?
|
| Troleandomycin | 1 | 2004 | 1 | 0.020 |
Why?
|
| Hypophysectomy | 1 | 2004 | 5 | 0.020 |
Why?
|
| Flavonoids | 1 | 2005 | 109 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2004 | 14 | 0.020 |
Why?
|
| Ketoconazole | 1 | 2004 | 6 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1447 | 0.020 |
Why?
|
| Creatinine | 1 | 2005 | 243 | 0.020 |
Why?
|
| Insecta | 1 | 2004 | 11 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 1040 | 0.020 |
Why?
|
| Isoniazid | 1 | 2004 | 20 | 0.020 |
Why?
|
| Plant Extracts | 1 | 2005 | 122 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2003 | 12 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 171 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2006 | 597 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 357 | 0.010 |
Why?
|
| Tablets | 1 | 2003 | 19 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 2003 | 21 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 710 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2004 | 205 | 0.010 |
Why?
|
| Fasting | 1 | 2003 | 75 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 282 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 1293 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 1342 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2673 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 21147 | 0.000 |
Why?
|